Bridging the Gap: How PointClickCare Life Sciences is Revolutionizing Drug Development

For decades, long-term and post-acute care (LTPAC) settings have been overlooked in the world of drug development, clinical research, and real-world data analysis. Pharmaceutical and biotech companies have traditionally focused on hospital and outpatient data, often neglecting a patient population that accounts for some of the highest levels of medication use and medical complexity. At PointClickCare Life Sciences, we are changing this narrative.

The Origins of PointClickCare Life Sciences

Our journey began with a simple yet profound realization: the data that PointClickCare has collected from skilled nursing and senior living facilities holds untapped potential. These settings are home to a patient population that is often underrepresented in clinical trials and real-world studies, despite their significant medical needs and medication usage.

For more than 20 years, PointClickCare has been collecting long-term care (LTC) and post-acute care data from the vast majority of senior care facilities across North America. This unique dataset offers insights at every stage of the healthcare journey, capable of fundamentally informing scientific research and the commercialization of new standards of care and revolutionary treatments.

The Unique Nature of Our Data Set

What sets PointClickCare Life Sciences apart is our access to the richest, continuously updated, and unrivaled data sets of aging and vulnerable populations. Our data set is not just large; it is rich and comprehensive, capturing the intricate details of patient care over extended periods. Here are some key examples that highlight the depth and breadth of our data:

• A decade of longitudinal data
• 7x more data volume than any other LTC data source
• Our data are representative of all adults in U.S. LTC
• Over 20 million unique patients
• ~9 billion daily vitals records
  • Vitals observations are being used by LS customers to understand health outcomes, medication efficacy, and even define conditions like Covid-19
    • 50 or more daily observations per patient
      • Blood pressure
      • Blood sugar
      • Height/Weight (BMI)
      • O2 saturation
      • Pain
      • Pulse
      • Respiration
      • Temperature
• 83 million assessment records and growing including
  • Functional Scores/Activities of Daily Living (ADL) – Almost 2 billion ADL records
  • Brief Interview of Mental Status/BIMS & Cognitive Performance Scale/CPS – Over 73 million Minimum Data Set (MDS) records
  • Depression/PHQ-9
• We deliver data updates weekly (near real-time)

Shaping Drug Development Across Therapeutic Areas

Our data is already making a significant impact in various therapeutic areas, including Alzheimer’s and related dementias, type 2 + type 3 diabetes, and tardive dyskinesia. Here’s how:

Alzheimer’s Disease and Related Dementias

Alzheimer’s is a complex and progressive condition that disproportionately affects the elderly. Our data provides insights into the long-term effects of different treatments, helping researchers and pharmaceutical companies develop more effective therapies. By understanding the real-world outcomes of current treatments, we can identify areas for improvement and innovation. Our dataset includes 6 years of patient journeys, offering unparalleled insights into the progression and management of Alzheimer’s.

Diabetes (Type 2 + Type 3)

Diabetes management is a lifelong process, and the elderly often face unique challenges in maintaining stable blood sugar levels. Our data set offers a detailed look at how different medications and lifestyle interventions impact long-term health outcomes. This information is invaluable for developing personalized treatment plans and improving patient care. With over 20 million unique patients and 9 billion daily vitals records, we provide a comprehensive view of diabetes management in long-term care settings.

Tardive Dyskinesia

Tardive dyskinesia is a condition characterized by involuntary movements, often a side effect of long-term medication use. Our data helps researchers understand the prevalence and progression of this condition in long-term care settings, enabling the development of more targeted and effective treatments. Our dataset includes over 73 million MDS records, providing a robust foundation for understanding and addressing tardive dyskinesia.

A Commitment to Innovation and Patient Care

At PointClickCare Life Sciences, we are committed to leveraging our unique data set to drive innovation and improve patient care. By providing pharmaceutical and biotech companies with the insights they need, we are helping to bridge the gap between clinical research and real-world practice. Our goal is to ensure that the needs of the elderly and those in long-term care are no longer overlooked.

A Growing Population

Life expectancies are increasing, and birth rates are falling in most developed countries, leading to aging populations. The 65+ age demographic is set to double in size in the U.S. by 2050, which will inevitably see drastic increases in the prevalence of age-related diseases. Unfortunately, this population faces delays in access to the same standards of care the general population receives, fueled by misconceptions regarding their ability to withstand or pay for treatment. In reality, members of this group take an average of six medications, representing $20B in branded drug sales and a rapidly growing market opportunity. PointClickCare Life Sciences aims to change the landscape for the aging population by supporting the innovation of urgently-needed therapeutic solutions.

Looking Forward

The future of drug development and clinical research is evolving, and we are proud to be at the forefront of this change. As we continue to grow and expand our data set, we are excited about the potential to make a meaningful difference in the lives of patients and the healthcare providers who care for them. Our continuously updated, longitudinal data provide insights supporting key strategic choices in the planning, implementation, and management of drug development processes, commercialization planning, sales strategies, and clinical trials.